Markets aren’t falling apart (SPY, AMZN, SLV, COST, KR, NFLX, APRN)
Markets aren’t falling apart, so I count that as a win. We swept the low from December 2018 yesterday, which should provide...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
The US FDA Approves The Expanded Manufacturing Process Of ADMA Biologics...
ADMA Biologics Inc (NASDAQ:ADMA) announced the US FDA approval for its expanded manufacturing process. It allows the company to manufacture IVIG (Intravenous Immune Globulin)...
MAKE IT MODERN
LATEST REVIEWS
Adverum Biotechnologies Inc (NASDAQ: ADVM) Completes Investigational New Drug Amendment for...
Adverum Biotechnologies Inc (NASDAQ: ADVM) has announced the completion of its Investigational New Drug (IND) amendment with the US FDA and is planning to...
MAKE IT MODERN
PERFORMANCE TRAINING
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) Develops An Oral Inhaled Anticalin Protein – PRS-220 To...
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) develops PRS-220 to treat IPF (idiopathic pulmonary fibrosis) by targeting CTGF (connective tissue growth factor).
Selected to receive a grant...
The Virus Testing Boom is Upon Us (CODX, DGX, RXMD, LH)
Trump even said it himself on Tuesday: “It’s going to get worse before it gets better.”
We keep hitting new highs among coronavirus infections, hospitalization,...
Apellis Pharmaceuticals Inc (NASDAQ:APLS) Releases Favorable Results From Phase 3 PEGASUS study As A...
Apellis Pharmaceuticals Inc (NASDAQ:APLS) recently its Phase 3 PEGASUS study results, where pegcetacoplan provides better results than eculizumab in combatting nocturnal hemoglobinuria (PNH).
The Phase...
VistaGen Therapeutics Inc (NASDAQ: VTGN) Reports Q1 2023 Financial Results And Provided Corporate Update
VistaGen Therapeutics Inc (NASDAQ: VTGN) has reported financial results for its fiscal Q1 2023 for the quarter ending June 230, 2022, and offered a...
Neurotrope Inc. (NASDAQ:NTRP) Announce Commencement Of New Long Term Study Bryostatin-1 in Treatment of...
Neurotrope Inc. (NASDAQ:NTRP) has announced the launch of a new second phase study of Bryostatin-1 for the treatment of Alzheimer's disease patients.
Neurotrope receives $2.7...
MAKE IT MODERN
